NKGen Biotech, Inc., a clinical-stage biotechnology company, develops cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells. Its lead products include SNK01, an autologous NK cell therapy candidate for the treatment of neurodegenerative diseases, and SNK02, an allogeneic NK cell therapy for refractory solid tumors. The company has a license agreement with NKMAX for its NK cell program. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California. Show more
Location: 3001 Daimler Street, Santa Ana, CA, 92705, United States | Website: https://nkgenbiotech.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
24.67M
52 Wk Range
$0.10 - $1.37
Previous Close
$0.33
Open
$0.33
Volume
400,881
Day Range
$0.28 - $0.38
Enterprise Value
45.56M
Cash
8.00K
Avg Qtr Burn
-5.217M
Insider Ownership
107.29%
Institutional Own.
1.66%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Troculeucel (SNK01) Details Alzheimer's disease | Phase 1/2 Data readout | |
SNK01 Details Parkinson's disease, Neurodegenerative disease | Phase 1/2 Initiation | |
SNK02 Details Solid tumor/s, Cancer | Phase 1 Update | |
Troculeucel (SNK01) Details no known indication | IND Submission |